CALL US:022-6101 1710   sales@saffronmedia.in
HOME NEWS INGREDIENT MART EVENTS TOPICS INTERVIEW EDIT
 
News
 
Yash Ved, Mumbai November 20 , 2026
Regulatory affairs have traditionally focused on securing marketing authorisations and maintaining approvals and recent regulatory developments have reinforced the importance of managing product quality throughout its lifecycle. While these remain fundamental responsibilities, regulatory expectations increasingly extend across the entire product lifecycle, from development and manufacturing to distribution and post-marketing surveillance, according to Sheetal Mudda, technical director, Misom Labs Limited, Malta.

Nitrosamine requirements, for example, demonstrate how emerging safety concerns can lead to reassessment of established products, additional testing, changes to specifications and regulatory variations. Similarly, EU GMP Annex 21 strengthens the link between overseas manufacturing, importation testing and ongoing product quality review, stated Mudda.

Mudda added, "Looking ahead, the forthcoming EU Pharmaceutical Package, comprising a new Directive and Regulation intended to replace the existing framework (Directive 2001/83/EC and Regulation 726/2004, governing pharmaceutical manufacturing, importation and marketing authorisation), represents a major legislative reform. It seeks to encourage innovation through revised regulatory data and market protection, broader Bolar exemptions, measures to combat antimicrobial resistance through incentives for new antibiotics, and provisions to improve medicine availability and security of supply."

These developments underline the importance of an integrated approach to regulatory affairs and pharmaceutical quality management. Regulatory considerations must be embedded in product development, quality risk management and change control, ensuring that regulatory commitments remain aligned with scientific knowledge, manufacturing capabilities and evolving product requirements throughout the lifecycle. This integration should begin during product development.

"Scientifically justified specifications, appropriate acceptance criteria and carefully evaluated regulatory commitments can prevent avoidable difficulties during commercial manufacturing and batch release. Timely assessment and coordinated implementation of variations across markets can similarly reduce delays and protect continuity of supply," stated Mudda.

Mudda further said that digitalisation and artificial intelligence offer further opportunities for regulatory intelligence, data management and lifecycle oversight, provided data integrity and appropriate human judgement are maintained. The evolving role of regulatory affairs is therefore not merely to secure and maintain approvals, but to connect regulatory requirements with quality systems and operational decisions throughout the product lifecycle. Such integration strengthens compliance, supports effective change management and helps ensure the continued availability of safe, effective and quality medicines.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
 
Website (required)
CommenT
Enter Code (Required)

 

 

 
INGREDIENT MART

RECENT NEWS

TOPICS
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...

 

MAIN LINKS OUR SERVICES OTHER PRODUCTS ONLINE MEDIA  
 
About Us
Contact Us
News Archives
 

Product Finder
Features and Articles
News
 
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
 
Media Information
Rate Card
Advertise
 
 
Copyright © 2023 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Chrome (103.0) or Firefox (90.0)